Pfizer's Core Leaders Outline Drive To Downsize In U.S., Europe While Expanding In BRIC Countries Including China
BEIJING - The core leaders of one of the globe's top pharmaceutical players - Pfizer Inc - told shareholders this week that they would push forward with a worldwide operation to reduce costs by downsizing in the West while ramping up sales forces in China and the other BRIC emerging markets
More from Archive
More from Scrip
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.